Glucocerebrosidase activity, cathepsin D and monomeric α-synuclein interactions in a stem cell derived neuronal model of a PD associated GBA1 mutation
The presence of GBA1 gene mutations increases risk for Parkinson's disease (PD), but the pathogenic mechanisms of GBA1 associated PD remain unknown. Given that impaired α-synuclein turnover is a hallmark of PD pathogenesis and cathepsin D is a key enzyme involved in α-synuclein degradation in n...
Main Authors: | Shi-yu Yang, Matthew Gegg, David Chau, Anthony Schapira |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2020-02-01
|
Series: | Neurobiology of Disease |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S0969996119302955 |
Similar Items
-
Cross-talks among GBA mutations, glucocerebrosidase, and α-synuclein in GBA-associated Parkinson’s disease and their targeted therapeutic approaches: a comprehensive review
by: Tapan Behl, et al.
Published: (2021-01-01) -
Ambroxol as a novel disease-modifying treatment for Parkinson’s disease dementia: protocol for a single-centre, randomized, double-blind, placebo-controlled trial
by: C. R. A. Silveira, et al.
Published: (2019-02-01) -
The Exosomal/Total α-Synuclein Ratio in Plasma Is Associated With Glucocerebrosidase Activity and Correlates With Measures of Disease Severity in PD Patients
by: Silvia Cerri, et al.
Published: (2018-05-01) -
A Human Neural Crest Stem Cell-Derived Dopaminergic Neuronal Model Recapitulates Biochemical Abnormalities in GBA1 Mutation Carriers
by: Shi-Yu Yang, et al.
Published: (2017-03-01) -
Glucocerebrosidase gene therapy prevents α-synucleinopathy of midbrain dopamine neurons
by: Emily M. Rocha, et al.
Published: (2015-10-01)